Maze Therapeutics, Inc. (NASDAQ:MAZE) Stock Has Consensus Price Target of $64.45

Maze Therapeutics, Inc. (NASDAQ:MAZE) has been assigned a consensus rating of “Buy” from the fourteen analysts that are presently covering the stock, MarketBeat reports. One research analyst has rated the stock with a sell rating, ten have assigned a buy rating and three have assigned a strong buy rating to the company. The average 1-year price target among brokerages that have covered the stock in the last year is $64.45.

MAZE has been the subject of several research analyst reports. Weiss Ratings reiterated a “sell (d-)” rating on shares of Maze Therapeutics in a research report on Monday, September 21st. Wall Street Zen lowered shares of Maze Therapeutics from a “hold” rating to a “sell” rating in a research report on Saturday, August 15th. Wedbush reiterated an “outperform” rating and issued a $48.00 price target on shares of Maze Therapeutics in a report on Wednesday, September 23rd. Citigroup initiated coverage on shares of Maze Therapeutics in a report on Wednesday, September 23rd. They set a “buy” rating and a $50.00 price objective on the stock. Finally, BTIG Research restated a “buy” rating and set a $46.00 target price on shares of Maze Therapeutics in a research report on Tuesday, September 22nd.

Maze Therapeutics Price Performance

Shares of MAZE opened at $31.48 on Monday. Maze Therapeutics has a twelve month low of $21.95 and a twelve month high of $53.65. The stock’s 50 day moving average is $27.49 and its two-hundred day moving average is $31.99. The firm has a market capitalization of $1.75 billion, a PE ratio of -12.49 and a beta of 2.03. The company has a current ratio of 18.31, a quick ratio of 18.31 and a debt-to-equity ratio of 0.09.

Maze Therapeutics (NASDAQ:MAZE) last issued its earnings results on Tuesday, August 11th. The company reported ($0.76) earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of ($0.76). Research analysts anticipate that Maze Therapeutics will post -2.70 earnings per share for the current year.

Insider Transactions at Maze Therapeutics

In related news, insider Courtney Phillips sold 2,012 shares of the firm’s stock in a transaction that occurred on Thursday, September 3rd. The stock was sold at an average price of $26.01, for a total value of $52,332.12. Following the completion of the transaction, the insider directly owned 7,007 shares of the company’s stock, valued at $182,252.07. This trade represents a 22.31% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, CEO Jason Coloma sold 34,501 shares of the firm’s stock in a transaction that occurred on Thursday, October 1st. The shares were sold at an average price of $27.02, for a total value of $932,217.02. Following the completion of the transaction, the chief executive officer directly owned 15,558 shares of the company’s stock, valued at $420,377.16. The trade was a 68.92% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last 90 days, insiders have sold 192,991 shares of company stock worth $5,187,559. 5.30% of the stock is currently owned by insiders.

Institutional Trading of Maze Therapeutics

Large investors have recently bought and sold shares of the company. Frazier Life Sciences Management L.P. boosted its position in shares of Maze Therapeutics by 10.2% in the 2nd quarter. Frazier Life Sciences Management L.P. now owns 5,032,915 shares of the company’s stock worth $150,182,000 after buying an additional 465,641 shares in the last quarter. TRV GP IV LLC acquired a new stake in Maze Therapeutics in the 2nd quarter valued at about $133,502,907. ARCH Venture Management LLC acquired a new stake in Maze Therapeutics in the 2nd quarter valued at about $122,983,582. BlackRock Inc. purchased a new position in Maze Therapeutics during the 2nd quarter valued at about $104,525,000. Finally, Jupiter Topco LLC purchased a new position in Maze Therapeutics during the 2nd quarter valued at about $101,764,000.

About Maze Therapeutics

Maze Therapeutics, Inc is a biopharmaceutical company focused on developing precision medicines for patients with genetically driven diseases. The company uses human genetics and its proprietary Maze Compass platform to identify disease mechanisms, discover drug targets and design therapies intended to address the underlying biology of serious conditions.

Maze’s pipeline has included small-molecule programs for rare diseases, including MZE001, an investigational glycogen synthase 1 inhibitor being developed for Pompe disease.